Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.

Lima VD, Gill VS, Yip B, Hogg RS, Montaner JS, Harrigan PR.

J Infect Dis. 2008 Jul 1;198(1):51-8. doi: 10.1086/588675.

PMID:
18498238
2.
3.

Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview.

Bartlett JA, Buda JJ, von Scheele B, Mauskopf JA, Davis EA, Elston R, King MS, Lanier ER.

J Acquir Immune Defic Syndr. 2006 Mar;41(3):323-31. Review. Erratum in: J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):381.

PMID:
16540933
4.
5.
6.

HIV update: emerging clinical evidence and a review of recommendations for the use of highly active antiretroviral therapy.

Kress KD.

Am J Health Syst Pharm. 2004 Oct 1;61 Suppl 3:S3-14; quiz S15-6. Review. Erratum in: Am J Health Syst Pharm. 2004 Nov 15;61(22):2350.

PMID:
15503932
7.

Optimal timing and best antiretroviral regimen in treatment-naive HIV-infected individuals with advanced disease.

Manzardo C, Zaccarelli M, Agüero F, Antinori A, Miró JM.

J Acquir Immune Defic Syndr. 2007 Sep;46 Suppl 1:S9-18. Review.

PMID:
17713424
8.

Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: a review.

Gianotti N, Soria A, Lazzarin A.

New Microbiol. 2007 Apr;30(2):79-88. Review.

9.

Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections.

Tan D, Walmsley S.

Expert Rev Anti Infect Ther. 2007 Feb;5(1):13-28. Review.

PMID:
17266450
10.

Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.

Zeldin RK, Petruschke RA.

J Antimicrob Chemother. 2004 Jan;53(1):4-9. Epub 2003 Dec 4. Review.

PMID:
14657084
11.
12.

Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.

Youle M.

J Antimicrob Chemother. 2007 Dec;60(6):1195-205. Epub 2007 Sep 21. Review.

PMID:
17890281
13.

HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.

Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA.

AIDS. 2009 Jan 28;23(3):279-91. doi: 10.1097/QAD.0b013e32831c54e5. Review.

PMID:
19114854
14.

Current and future antiretroviral treatment options in paediatric HIV infection.

Giaquinto C, Morelli E, Fregonese F, Rampon O, Penazzato M, de Rossi A, D'Elia R.

Clin Drug Investig. 2008;28(6):375-97. Review.

PMID:
18479179
15.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].

Panel de expertos de Gesida y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2009 Oct;27(8):491.

PMID:
19246124
16.

Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options.

Naggie S, Hicks C.

J Antimicrob Chemother. 2010 Jun;65(6):1094-9. doi: 10.1093/jac/dkq130. Epub 2010 Apr 23. Review.

PMID:
20418273
17.

Protease inhibitor-based regimens for HIV therapy: safety and efficacy.

Walmsley S.

J Acquir Immune Defic Syndr. 2007 Jun 1;45 Suppl 1:S5-13; quiz S28-31. Review.

PMID:
17525691
18.

Double-boosted protease inhibitor antiretroviral regimens: what role?

Ribera E, Curran A.

Drugs. 2008;68(16):2257-67. doi: 10.2165/0003495-200868160-00001. Review.

PMID:
18973392
19.

Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection.

Kaplan SS, Hicks CB.

J Antimicrob Chemother. 2005 Aug;56(2):273-6. Epub 2005 Jun 30. Review.

PMID:
15994247
20.

Protease-inhibitor boosting in the treatment-experienced patient.

Gallant JE.

AIDS Rev. 2004 Oct-Dec;6(4):226-33. Review.

PMID:
15700621

Supplemental Content

Support Center